Quick Answer
Anebulo Pharmaceuticals, Inc. reported Research And Development Expense of $4.30 million for the year ending 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +21.2% in Research And Development Expense from 2024 to 2025.
- This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 5 years of available data (2021 to 2025), Anebulo Pharmaceuticals, Inc.'s Research And Development Expense has grown by 89.4%.
- Historical annual values: Fiscal year 2025: $4.30 million | Fiscal year 2024: $3.55 million | Fiscal year 2023: $5.60 million | Fiscal year 2022: $2.96 million | Fiscal year 2021: $2.27 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: